Study of mRNA-1010 Seasonal Influenza Vaccine in Adults

Completed · Phase 3 · NCT05827978

Conditions: Seasonal Influenza

Research payments reported, 2025: $2.3M
U.S. investigators named: 51
Sites paid: 37
Planned or actual enrollment: 8,411

About the trial

Sponsor: ModernaTX, Inc.
Tested: mRNA-1010 (biological), Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine (biological)
Dates: Started 2023-04-17; completion 2024-06-24
Results posted: Yes

This study includes 3 parts: Parts A, B, and C. The purpose of this study is to evaluate the immunogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults.

From ClinicalTrials.gov, last updated 2025-07-10. Full record, eligibility and contacts (opens in a new tab)

Industry funding

ModernaTX, Inc. reported $2.3M in research payments for this study in 2025 (265 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.

At a glance

About the trial

Industry funding

U.S. investigators named on this study

Sites paid to run it